Skip to main content
Figure 2 | Respiratory Research

Figure 2

From: Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts

Figure 2

Roflumilast and indacaterol inhibition of CTGF transcript is PKA-dependent. For all experiments, NHLF were pretreated with compound or vehicle control for 1 h and RNA was made 6 h after TGFβ1 (10 ng/mL) treatment. (C) For experiments with H89 (10 μM), inhibitor was added 30 min before compound pretreatment, with open bars (+H89) and checked bars (-H89) treatment. All data represents the MFI normalized to PPIB and fold induction calculated versus non-stimulated control. The data represent the mean ± SEM for n = 5 (A), n = 8 (B) and n = 3 (C) experiments, run in triplicate. ROF: roflumilast, INDA: indacaterol. (B) ***p < 0.001 as compared to TGFβ1 vehicle-treated cells, ##p < 0.01 and ###p < 0.001 as compared to roflumilast treated cells. (C) *p < 0.05, **p < 0.01 as compared to H89 negative control.

Back to article page